Currently, there are 167.82M common shares owned by the public and among those 117.03M shares have been available to trade.
The company’s stock has a 5-day price change of 52.03% and 112.26% over the past three months. ATAI shares are trading 69.17% year to date (YTD), with the 12-month market performance up to 24.31% higher. It has a 12-month low price of $1.03 and touched a high of $2.85 over the same period. ATAI has an average intraday trading volume of 1.90 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 42.95%, 48.77%, and 55.59% respectively.
Institutional ownership of ATAI Life Sciences N.V (NASDAQ: ATAI) shares accounts for 7.16% of the company’s 167.82M shares outstanding.
It has a market capitalization of $377.55M and a beta (3y monthly) value of 1.18. The earnings-per-share (ttm) stands at -$0.80. Price movements for the stock have been influenced by the stock’s volatility, which stands at 18.12% over the week and 11.45% over the month.
Earnings per share for the fiscal year are expected to decrease by -217.14%, and 21.17% over the next financial year.
Looking at the support for the ATAI, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on November 18, 2024, with the firm’s price target at $15-$10. Maxim Group coverage for the ATAI Life Sciences N.V (ATAI) stock in a research note released on April 03, 2024 offered a Buy rating with a price target of $6. Loop Capital was of a view on November 01, 2022 that the stock is Buy, while Maxim Group gave the stock Buy rating on November 30, 2021, issuing a price target of $25. ROTH Capital on their part issued Buy rating on November 11, 2021.
